Scientific results are shown on posters at congresses

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.

Here, we will give a short insight into our published results: Original publications

Eingeschlossene Patienten: 21.686 (Stand 1. Dezember 2022) 
Amgevita® (Adalimumab)162
Benepali® (Etanercept)1007
Cimzia® (Certolizumab)993
Enbrel® (Etanercept)2870
Erelzi® (Etanercept)430
Flixabi® (Infliximab)10
Hulio® (Adalimumab)162
Humira® (Adalimumab)2904
Hyrimoz® (Adalimumab)152
Idacio® (Adalimumab)44
Imraldi® (Adalimumab)156
Inflectra™ (Infliximab)16
Jyseleca® (Filgotinib)86
Kevzara® (Sarilumab)184
Kineret® (Anakinra)89
MabThera® (Rituximab)1459
Nepexto® (Etanercept)33
Olumiant® (Baricitinib)508
Orencia® (Abatacept)926
Remicade® (Infliximab)762
Remsima® (Infliximab)15
Rinvoq® (Upadacitinib)263
Rixathon® (Rituximab)19
RoActemra® (Tocilizumab)1338
Ruxience® (Rituximab)1
Simponi® (Golimumab)454
Xeljanz® (Tofacitinib)387
Zessly® (Infliximab)2